Athersys licenses stem cell technology in deal worth up to $40M
RTI Biologics Inc. plans to develop and commercialize implants based on Athersys' Multipotent Adult Progenitor Cell (MAPC) technology.
Athersys board member resigns
As of Sept. 9, Michael Sheffery, a general partner with New York-based venture firm OrbiMed Advisors, no longer is a member of Athersys' board.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Athersys shares fall on judge’s stem cell decision
A judge's ruling that blocks federal funding for embryonic stem cell research triggered a tumble for shares of Cleveland biopharmaceutical company Athersys Inc. (NASDAQ: ATHX) -- even though its business involves only adult stem cells.
Power of Athersys stem cells may be underestimated, analyst says
WBB Securities analyst Steve Brozak isn't sure whether people understand how much better the stem cell therapy of Cleveland, Ohio-based Athersys Inc. is for treating heart attacks than the standard-of-care treatment. Brozak raised his rating on Athersys stock to "strong buy" from "buy" in light of clinical evidence that could change the way heart attack patients are treated.
Athersys repeats good heart attack study results; reports 2Q loss
As expected, biopharmaceutical company Athersys Inc. (NASDAQ: ATHX) reported late Monday afternoon "several key developments" in testing and commercializing its adult stem cell therapy to treat heart attacks and inflammatory bowel disease, among other disorders. The development-stage company lost money in the second quarter: $3.1 million, or 16 cents a diluted share. That was slightly better than a loss of $3.3 million, or 18 cents a diluted share, in the same quarter a year ago. But revenue more than quadrupled to $1.9 million from $436 million a year ago.
Athersys stem cell therapy could offer new heart attack treatment
Updated 6:31 p.m. While guarding against making too much of a small Phase 1 study, Athersys Inc. (NASDAQ: ATHX) leaders hinted late Wednesday that their adult stem cell therapy MultiStem eventually could change the way people are treated for heart attacks. The Cleveland, Ohio, biopharmaceutical company reported early results from an ongoing Phase 1 trial […]
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Ohio Third Frontier Commission awards $14M in biomedical grants
Ohio Third Frontier commissioners made a slew of biomedical grants under two programs today. Recommended for more than $4.9 million under the Ohio Third Frontier Biomedical Program: — CardioX Corp., Dublin, in collaboration with Nottingham-Spirk Design Associates in Cleveland and QTest Labs in Columbus, was awarded $986,373 to finalize designs and clinical protocols for a […]
Experts laud potential of Athersys stem cell therapy MultiStem
Doctors and researchers at the Athersys Inc. (NASDAQ: ATHX) investor meeting in New York City expressed hope that the company’s stem cell therapy — MultiStem — could raise the ceiling on care for heart attack, stroke and some cancer patients, among others. Biopharmaceutical company Athersys invited nearly a dozen stem cell experts — including Ruth […]
Athersys still excited about Pfizer stem cell collaboration
Updated 2:49 p.m., May 7, 2010. Biopharmaceutical company Athersys Inc. (NASDAQ: ATHX) is excited to be working with Pfizer Regenerative Medicine on a stem cell treatment for inflammatory bowel disease. But you’ll have to attend the Cleveland company’s 2010 investor and research & development day in New York City on May 14 to find out […]
Ohio drug, therapy companies share limelight at BIO convention
The Biotechnology Industry Organization international convention returns to Chicago this week — a nod to the importance of pharmaceutical and therapeutic companies in Midwestern states like Ohio. Drugmaking has history in Ohio. From Procter & Gamble Pharmaceuticals (NYSE: PG) in Cincinnati (sold last year to Irish drug company Warner Chilcott), to generic drugmakers Ben Venue […]
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Athersys executives excited about stem cell, drug programs
Executives of biopharmaceutical company Athersys Inc. seem more confident than ever that their stem cell therapy MultiStem could eventually be used to profoundly help patients recover from heart attack, stroke or leukemia. In a conference call with securities analysts late Thursday afternoon, the executives also disclosed promising research on drug candidates to treat obesity and […]
OrbiMed Advisors raises $550M for health venture fund
OrbiMed Advisors, which has invested in Ohio companies Athersys Inc. and ViewRay, has raised $550 million for its latest health venture capital fund.
Athersys finishes enrolling heart attack patients for stem cell therapy study
Biopharmaceutical company Athersys Inc. has finished enrolling patients for a Phase 1 clinical trial of its MultiStem adult stem cell therapy to treat heart attack victims. The company expects to begin reporting safety and maximum-tolerated dose results by mid-year.
Athersys gets U.S., European patents for investigational stem cell therapy
Biopharmaceutical company Athersys Inc. has received two patents that extend protection of its investigational stem cell therapy and how it's produced and used.
Biopharmaceutical company Athersys seeks to register 20 million shares, warrants for future sale
Biopharmaceutical company Athersys Inc. is seeking to register 20 million shares of common stock, or warrants to buy the stock, which the company might or might not sell in the future. If all of the shares or warrants eventually are sold, it could mean gross proceeds of more than $70 million for the stem cell therapy and drug developer.